GFP
SUPN icon

Gryphon Financial Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Gryphon Financial Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-4,037
Closed -$204K – 224
2018
Q3 		$204K Buy
4,037
+3,034
+302% +$150K 0.06% 146
2018
Q2 		$60K Hold
1,003
– – 0.03% 197
2018
Q1 		$46K Sell
1,003
-178
-15% -$7.43K 0.02% 241
2017
Q4 		$47K Buy
+1,181
New +$46.7K 0.03% 257

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Gryphon Financial Partners's SUPN Position: Q4 2018 in Review

Gryphon Financial Partners sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 4,037 shares — an estimated $204K sold.

Gryphon Financial Partners first reported a position in SUPN in Q4 2017 and held it in 4 quarters. The position peaked at $204K in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Gryphon Financial Partners reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Gryphon Financial Partners sold 4,037 Supernus Pharmaceuticals shares in Q4 2018, an estimated $204K.
  • Gryphon Financial Partners first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Gryphon Financial Partners's Supernus Pharmaceuticals position peaked at $204K in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Gryphon Financial Partners's 13F filing for Q4 2018, filed 11 Feb 2019.